We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Beta-CIT-SPECT and Neurophysiology in Depression

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00145132
First Posted: September 5, 2005
Last Update Posted: June 2, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
H. Lundbeck A/S
Information provided by:
Ludwig-Maximilians - University of Munich
September 1, 2005
September 5, 2005
June 2, 2010
June 2005
December 2009   (Final data collection date for primary outcome measure)
changes in β-CIT/neurophysiological measurements from baseline to week 4 [ Time Frame: two assessments, at baseline and week 4 ]
changes in β-CIT/neurophysiological measurements from baseline to week 4
Complete list of historical versions of study NCT00145132 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Beta-CIT-SPECT and Neurophysiology in Depression
Serotonin and Dopamine Transporter (SERT, DAT) Availabilities as Assessed by b-CIT and SPECT, and Neurophysiological Measures of Central Serotonergic Activity in Patients With Depression Under Treatment With Escitalopram
Aim of this project is to investigate the effects of escitalopram on monoamine transporter (SERT, DAT) availabilities as assessed by b-CIT and SPECT, and on neurophysiological parameters such as the loudness dependence of auditory evoked potentials (LDAEP) in patients with depression.
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Depression
Procedure: β-CIT-SPECT, Neurophysiology
β-CIT-SPECT scans and EEG recordings, two assessments each
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
December 2009
December 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Psychiatric in or outpatients with acute depressive episode
  • Indication for pharmacological treatment

Exclusion Criteria:

  • Acute suicidality
  • Neurological or severe somatic disorders
  • Occupational exposition to radiation >15 mSv per year
  • Women during pregnancy or lactation
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00145132
ESCIT-SPECT-Pogarell
EK287/98
Not Provided
Not Provided
Not Provided
Oliver Pogarell, MD, University of Munich
Ludwig-Maximilians - University of Munich
H. Lundbeck A/S
Principal Investigator: Oliver Pogarell, MD Dept. of Psychiatry, University of Munich
Ludwig-Maximilians - University of Munich
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP